* LifeMD Inc LFMD.OQ LFMD.O is expected to show a rise
in
quarterly revenue when it reports results on August 7 for the
period ending June 30 2024
* The New York City-based company is expected to report a
34.2% increase in revenue to $48.251 million from $35.95 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.The company's guidance on May 8 2024, for the
period ended June 30, was for revenue between $48.00 million and
$50.00 million.
* LSEG's mean analyst estimate for LifeMD Inc is for a loss
of 12
cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for LifeMD Inc
is
$12.00, above its last closing price of $5.98.
The company's guidance on May 8 2024 for the period ended June
30 was for Earnings before Interest, Taxes, Depreciation and
Amortization of between USD48 million and USD3 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -0.16 -0.15 -0.19 Missed -23.4
Dec. 31 2024 -0.12 -0.14 -0.12 Beat 14.3
Sep. 30 2023 -0.15 -0.15 -0.20 Missed -29
Jun. 30 2023 -0.10 -0.10 -0.23 Missed -122.6
Mar. -0.16 -0.16 -0.15 Beat 6.3
31 2023
Dec. 31 2022 -0.18 -0.18 -0.40 Missed -122.2
Jan. 1 0001 -0.30 -0.28 -0.26 Beat 8.8
Jun. 30 2022 -0.35 -0.35 -0.45 Missed -28.6
This summary was machine generated August 6 at 02:22 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)